Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J AngioGuard Emboli Capture Device Purchase Portends SMART Bundle

This article was originally published in The Gray Sheet

Executive Summary

Clinical trials of Johnson & Johnson's SMART stent for carotid revascularization procedures and AngioGuard's emboli capture device could dovetail following J&J's acquisition of the Minneapolis-based start-up, announced July 7.

You may also be interested in...



PercuSurge Committed To Boston Scientific Carotid Stent Trial

PercuSurge will proceed with plans to conduct U.S. trials of its GuardWire distal protection device with Boston Scientific's WallStent for carotid angioplasty, in spite of rival Medtronic's proposed purchase of the company for $225 mil., announced Oct. 19.

PercuSurge Committed To Boston Scientific Carotid Stent Trial

PercuSurge will proceed with plans to conduct U.S. trials of its GuardWire distal protection device with Boston Scientific's WallStent for carotid angioplasty, in spite of rival Medtronic's proposed purchase of the company for $225 mil., announced Oct. 19.

Boston Scientific Embol-X Buy Readies Firm For Carotid Stent Race

Boston Scientific's acquisition of embolic protection technology developed by Embol-X may help level the playing field with competitors Guidant and Johnson & Johnson in the race to bring carotid stent technology to market.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel